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The first cases of COVID-19 were detected in South Africa (SA) on 
5 March 2020, and in Cape Town on 11 March.[1] Subsequently case 
numbers have escalated exponentially. Western Cape Province was 
the initial epicentre with the highest prevalence of confirmed cases, 
with just over 60% of all cases in SA. The majority of these were 
within the Cape Town metropole.[2] At the time of writing, Tygerberg 
Hospital, a 1 380-bed tertiary referral hospital for both the Tygerberg 
and Khayelitsha (low-income) subdistricts, has had the greatest 
number of COVID-19 patients in the Western Cape.[3]
The potential impact and mortality of COVID-19 in SA are 
unknown at this stage. Although SA has a relatively young population 
(median age 25 years),[4] many South Africans of all ages have risk 
factors for severe COVID-19 disease identified in other populations. 
Adult South Africans have an unusually high background prevalence 
of hypertension (41.6 - 54%),[5] diabetes (12.8%)[6] and obesity 
(68% of females, 31% of males).[7] Non-communicable diseases are 
estimated to cause 43% of adult deaths in SA, of which 18% are 
caused by cardiovascular disease.[8]
Of further concern is that SA has the world’s highest number 
of people living with HIV (PLHIV), estimated at 7.7 million.[9] It 
is unknown what impact HIV, both treated and untreated, will 
have on COVID-19 outcomes. Furthermore, SA has one of the 
highest incidence rates of tuberculosis (TB) globally, 520/100 000 
population in 2018,[10] and the interaction of COVID-19 with TB is 
not clear. The importance of gaining early insights into the COVID-
19 pandemic on the African continent, especially for PLHIV, cannot 
be overstated. At-risk populations need to be urgently identified and 
managed appropriately, in a manner that is contextually relevant to 
the available resources.
Objectives
To describe the clinical features, comorbidities and outcome of 
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Background. South Africa (SA) has a high prevalence of HIV and tuberculosis. Cape Town was the SA metropole most affected in the 
early stages of the COVID-19 pandemic. Early observational data from Africa may provide valuable insight into what can be expected as 
the pandemic expands across the continent.
Objectives. To describe the prevalence, clinical features, comorbidities and outcome of an early cohort of HIV-positive and HIV-negative 
patients admitted with COVID-19.
Methods. This was a descriptive observational study of an early cohort of adults with COVID-19 pneumonia admitted from 25 March to 
11 May 2020.
Results. Of 116 patients (mean age 48 years, 61% female) admitted, 24 were HIV-positive (21%). The most common symptoms reported 
were cough (n=88; 73%), shortness of breath (n=78; 69%), fever (n=67; 59%), myalgia (n=29; 25%) and chest pain (n=22; 20%). The 
most common comorbidities were hypertension (n=46; 41%), diabetes mellitus (n=43; 38%), obesity (n=32; 28%) and HIV (n=24; 21%). 
Mortality was associated with older age (mean (standard deviation) 55 (12) years v. 46 (14) years; p<0.01); the presence of hypertension or 
hypertension along with diabetes and/or obesity; lower partial pressure of arterial oxygen to fraction of inspired oxygen ratio; and higher 
urea level, white cell count, neutrophil count, and C-reactive protein, lactate dehydrogenase and ferritin levels, and high neutrophil to 
lymphocyte ratio. The overall survival rate for all hospital admissions was 86/116 (73%). In this early cohort, survival was similar in patients 
with HIV (n=18; 75%) compared with those without HIV (n=67; 75%) (p=1). Of the 74 patients admitted to the wards, 63 (85%) survived, 
whereas 22 of 42 (52%) admitted to the intensive care unit survived.
Conclusions. Patients with HIV infection represented a large proportion of all COVID-19 admissions. The presentation and outcome of 
patients with HIV did not differ significantly from those of patients without HIV.
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an early cohort of confirmed COVID-19 
pneumonia patients admitted to a dedicated 
COVID-19 hospital, and specifically 
describe the prevalence, clinical profile and 
outcome of PLHIV.
Methods
Study design, setting and population
This single-centre descriptive study included 
all consecutive patients aged >18 years with 
a SARS-CoV-2-positive polymerase chain 
reaction result and radiological evidence 
compatible with COVID-19 pneumonia 
admitted to Tygerberg Hospital, Cape Town, 
between 24 March and 11 May 2020.
Data collection
Patients admitted to Tygerberg Hospital 
with COVID-19 were identified from the 
hospital COVID Unit’s application-based 
registry. The registry was verified against 
nursing and administrative records in each 
of the COVID wards to ensure accuracy 
and completeness. Data were extracted 
from hospital records and laboratory 
results, using a standardised form, and 
included demographic details, symptoms, 
comorbidities, blood results, imaging results, 
admission to the ward or the intensive 
care unit (ICU), length of admission, and 
outcome (death or discharge). HIV status 
was obtained in all patients. Where the HIV 
status was negative or unknown, an HIV 
enzyme-linked immunosorbent assay was 
done on admission. Glycated haemoglobin 
(HbA1C) was measured on admission at the 
discretion of the primary caregivers. Where 
not available during the admission, the 
HbA1C within 4 months prior to admission 
was recorded. Obesity was documented 
on the standardised admission tool at the 
discretion of the primary caregivers.
Chest radiographs were categorised 
according to type and distribution of 
infiltrates by the consensus of two specialists 
from the Division of Pulmonology at 
Tygerberg Hospital. Infiltrates were classi-
fied as consolidation, alveolar, reticular or 
micronodular. Distribution of infiltrates 
was categorised into laterality (peripheral, 
central or diffuse) and distribution (basal, 
apical or diffuse).
All patients were followed up until 
discharge from hospital or death. The data 
were complete as at 23 May 2020.
Statistical analyses
Descriptive numerical data with a normal 
distribution were described using means 
and standard deviations (SDs), whereas non-
normal data were described using medians 
and interquartile ranges (IQRs). Chi-square 
or Fisher’s exact tests were used to identify 
statistical significance for all categorical 
outcomes. When comparing the means of 
continuous data, the t-test was used when 
the data had a normal distribution and the 
Mann-Whitney U-test when the data did not 
have a normal distribution.
Statistical significance was set at p<0.05, 
and a 95% confidence interval was used.
Ethics approval
The study was approved by the Health 
Research Ethics Committee of Stellenbosch 
University (ref. no. N20/04/002_COVID-19).
Results
Baseline data
We identified 116 patients with COVID-19 
admitted during the study period, and all 
were included in the analysis. Demographic 
and laboratory data were available for all 
patients. Clinical data including symptoms 
and comorbidities were available for 113 
patients and chest radiographs for 115. 
Outcome data were available for all patients. 
The first patient was admitted on 25 March 
2020 and the 116th patient on 11 May. Patient 
numbers increased gradually throughout the 
study period (Fig. 1).
The mean (SD) age of patients was 48 (14) 
years, and there were more females (n=71; 
61%) than males (n=45; 39%). Patients who 
died were older than those who survived 
(mean (SD) age 55 (12) years v. 46 (14) years, 
respectively; p<0.01).
The prevalence of HIV (n=24) in this 
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Fig. 1. Admissions over time. (ICU = intensive care unit.)
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a mean (SD) age of 46 (9) years, with 18 (75%) being female. The 
mean (SD) CD4+ count (n=16 patients) was 325 (206) cells/µL. 
Seventeen patients (71%) were on antiretroviral therapy (ART) with 
suppressed HIV viral loads, 1 patient (4%) was on ART but was 
failing the regimen, 4 patients (17%) had a history of defaulting ART, 
and 2 patients (8%) were ART naive. Patients with HIV had a trend 
towards shorter duration of symptoms prior to admission (5.4 v. 
7.3 days; p=0.26).
A total of 4 patients (3.5%) reported being on treatment for TB, 
while 9 (8%) gave a history of previous TB. A history of smoking was 
present in 8 cases (7%).
Clinical features
The most common reported symptom was cough (n=88; 73%). This 
was followed by shortness of breath, fever, myalgia, chest pain and 
malaise (Table 1). Diarrhoea was reported by 13% of patients. Sore 
throat was infrequently reported. Symptoms in patients with HIV 
were similar, and none had sore throat as a presenting symptom.
The most common comorbidity reported was hypertension, 
followed by diabetes mellitus, obesity and HIV (Table 2). The 
presence of hypertension or hypertension along with diabetes and/or 
obesity was associated with high mortality.
Of the patients with HIV, 16 (76%) had at least one other 
comorbidity (Table 3). The most common comorbidities in the 
HIV-positive patients were diabetes, hypertension and obesity. HIV-
positive patients were also more likely than those who were HIV-
negative to have a prior history of TB (n=6; 25% v. n=3; 3%; p<0.01).
Table 1. Symptoms at baseline (N=113)
n (%)
Cough 88 (77.9)
Shortness of breath 78 (69.0)
Fever 67 (59.3)
Myalgia 29 (25.7)




Sore throat 12 (10.6)
Loss of smell 11 (9.7)
Loss of taste 8 (7.1)
Abdominal pain 8 (7.1)
Haemoptysis 3 (2.7)
Table 2. Comorbidities according to patient outcome (N=113)
Survivors (N=85), n (%) Deaths (N=28), n (%) OR 95% CI p-value
Hypertension 30 (35.3) 16 (57.1) 2.4 1.0 - 5.8 0.07
Diabetes 29 (34.1) 14 (50.0) 1.9 0.8 - 4.6 0.20
Hypertension + diabetes 19 (22.4) 11 (39.3) 2.3 0.9 - 5.6 0.13
Hypercholesterolaemia 8 (9.4) 2 (7.1) 0.7 0.2 - 3.7 1
Obesity 23 (27.1) 9 (32.1) 1.3 0.5 - 3.2 0.78
Hypertension + diabetes + obesity 7 (8.2) 6 (21.4) 3.0 0.9 - 10.0 0.08
Cardiac disease 5 (5.9) 1 (3.6) 0.6 0.1 - 5.3 1
Malignancy 1 (1.2) 0 0 n/a 1
HIV 18 (21.2) 6 (21.4) 1.0 0.4 - 2.9 0.81
Current tuberculosis 2 (2.4) 2 (7.1) 3.2 0.4 - 23.8 0.26
Previous tuberculosis 5 (5.9) 4 (14.3) 2.7 0.7 - 10.7 0.22
Other chronic lung disease 3 (3.5) 3 (10.7) 3.3 0.6 - 17.3 0.16
Connective tissue disease 1 (1.2) 0 0 n/a 1
Chronic kidney disease 5 (5.9) 3 (10.7) 1.9 0.4 - 8.6 0.41
CI = confidence interval; n/a = not applicable.







Age (years), mean 46.2 49.1 0.20
Male, n (%) 6 (25.0) 38 (42.7) 0.18
Female, n (%) 18 (75.0) 51 (57.3) 0.18
Symptoms, n (%)    
Cough 17 (70.8) 71 (79.8) 0.51
Haemoptysis 2 (8.3) 1 (1.1) 0.11
Dyspnoea 17 (70.8) 61 (68.5) 1.00
Fever 15 (62.5) 52 (58.4) 0.89
Sore throat 0 12 (13.5) 0.07
Loss of smell 1 (4.2) 10 (11.2) 0.45
Loss of taste 0 8 (9.0) 0.20
Diarrhoea 4 (16.7) 11 (12.4) 0.73
Abdominal pain 1 (4.2) 7 (7.9) 0.69
Chest pain 5 (20.8) 17 (19.1) 1.00
Headache 1 (4.2) 14 (15.7) 0.19
Malaise 4 (16.7) 12 (13.5) 0.74
Myalgia 5 (20.8) 24 (27.0) 0.73
Comorbidities, n (%)    
Hypertension 8 (33.3) 38 (42.7) 0.55
Diabetes 10 (41.7) 33 (37.1) 0.86
Dyslipidaemia 1 (4.2) 9 (10.1) 0.46
Obesity 5 (20.8) 27 (30.3) 0.51
Cardiac disease 1 (4.2) 5 (5.6) 1.00
Malignancy 0 1 (1.1) 1.00
Current TB 2 (8.3) 2 (2.2) 0.21
Previous TB 6 (25.0) 3 (3.4) <0.01
 Other chronic lung disease 2 (8.3) 4 (4.5) 0.61
Connective tissue disease 0 1 (1.1) 1.00
Chronic kidney disease 2 (8.3) 6 (6.7) 1.00
TB = tuberculosis.
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Investigations
A low partial pressure of arterial oxygen to fraction of inspired oxygen 
(P/F) ratio and a high white cell count, neutrophil count, neutrophil 
to lymphocyte (N/L) ratio, and C-reactive protein (CRP), lactate 
dehydrogenase and ferritin levels were strongly associated with death. 
An elevated cardiac troponin level had a tendency to be associated with 
death, but this was not statistically significant (Table 4).
There was no significant difference in laboratory values between 
the HIV-positive and HIV-negative patients, except that patients with 
HIV were more likely to have anaemia at baseline.
Most patients had bilateral reticular infiltrates on chest 
radiography (n=88; 77%) (Table 5). Seven patients had radiological 
evidence of underlying structural lung disease. These included post-
tuberculous lung disease (n=4), interstitial lung disease (n=2) and 
aspergilloma (n=1). None of the chest radiographs had evidence 
of chronic obstructive pulmonary disease. Micronodular infiltrates 
were strongly associated with mortality (18/30; 60% v. 21/85; 25%; 
p=0.001), while there was a trend towards increased mortality in 
patients with consolidation (p=0.06) and alveolar infiltrates (p=0.08). 
Reticular infiltrates were not associated with mortality.
Most of the patients with HIV had bilateral reticular (19/24; 79%) 
or micronodular infiltrates (9/24; 38%). Patients with HIV were more 
likely than those without HIV to have underlying structural lung 
disease (4/24; 17% v. 3/88; 3%, respectively; p=0.04). This included 
post-tuberculous lung disease in 3 patients, and an aspergilloma in 
1 patient.
Outcome
Most patients (64%) were admitted to the general ward (n=74), and 
36% were admitted to the ICU (n=42). When compared with HIV-
negative patients, more HIV-positive patients tended to be admitted 
to the wards (n=19; 79% v. n=55; 62%) than to the ICU (n=5; 21% 
v. n=34; 38%; p=0.18). In the wards the median (IQR) length of stay 
(LoS) was 6 (3 - 10) days and in the ICU it was 6 (3 - 10) days. HIV-
positive patients had a similar LoS (6 (IQR 3.5 - 10.5, range 0 - 26) 
days) to HIV-negative patients (6 (IQR 3 - 10, range 0 - 28) days). In 
this early cohort, the median time from admission to ICU admission 
was <1 day. For the patients discharged from the ICU, the median 
(IQR) LoS was 15.5 (10 - 17) days.
The overall survival rate of all admissions was 86/116 (73%). In this 
early cohort, survival was similar in patients with HIV (n=18; 75%) 
compared with those without HIV (n=67; 75%). Survival for patients 
admitted to the wards was 85% (63/74) and that for patients admitted 
to the ICU was 52% (22/42).
Table 4. Baseline arterial blood gas and laboratory results in survivors and non-survivors
                              Survivors Non-survivors
p-valuen Mean (SD) 95% CI n Mean (SD) 95% CI
Arterial blood gas
SaO2 (%) 61 94 (5.1) 93 - 95 19 82 (14.1) 75 - 89 0.001
PaO2 (kPa) 64 10.5 (4.2) 9.5 - 11.5 25 8.1 (4.4) 6.3 - 9.9 0.03
FiO2 (%) 67 33 (0.19) 28 - 38 24 41 (0.27) 30 - 52 0.17
P/F ratio 63 288 (156) 249 - 327 24 188 (112) 141 - 235 0.002
PaCO2 (kPa) 63 4.7 (1.3) 4.4 - 5.0 24 5.1 (2.4) 4.1 - 6.1 0.44
pH 63 7.44 (0.06) 7.42 - 7.46 25 7.41 (0.11) 7.35 - 7.45 0.10
Bloods  
Sodium (mmol/L) 84 136 (4.3) 135 - 137 31 137 (8.0) 134 - 140 0.77
Potassium (mmol/L) 76 4.2 (0.6) 4.1 - 4.3 31 4.3 (0.9) 4.0 - 4.6 0.75
Urea (mmol/L) 85 6.0 (5.3) 4.9 - 7.2 31 12.0 (12.1) 7.6 - 16.4 0.01
Creatinine (µmol/L) 85 101 (150) 69 - 133 31 194 (321) 77 - 311 0.13
WCC (× 109/L) 84 7.8 (3.8) 7.0 - 8.6 31 11.6 (6.7) 9.2 - 14.0 0.004
Neutrophils (× 109/L) 77 5.95 (3.92) 5 - 7 28 9.22 (6.40) 6.74 - 11.7 0.02
Lymphocytes (× 109/L) 77 1.55 (1.87) 1.13 - 1.97 28 1.44 (1.46) 0.87 - 2.01 0.76
N/L ratio 74 6 (6) 5 - 7 28 10 (9) 7 - 13 0.06
Haemoglobin (g/dL) 84 12.13 (2.6) 11.43 - 12.57 31 11.72 (2.0) 11.27 - 12.73 0.37
MCV (fL) 83 88 (7.7) 86 - 90 31 90 (6.9) 88 - 93 0.17
Platelets (× 109/L) 84 285 (125) 259 - 312 31 303 (149) 248 - 358 0.55
C-reactive protein (mg/L) 72 128 (105) 103 - 153 31 204 (102) 167 - 241 0.001
LDH (U/L) 46 400 (165) 351 - 449 20 658 (199) 565 - 751 <0.0001
ALT (U/L) 52 36 (30) 28 - 44 22 38 (32) 24 - 52 0.77
Troponin T (ng/L) 15 17 (15) 9 - 26 11 65 (84) 8 - 122 0.09
Creatine kinase (U/L)* 6 56 (28 - 1 218) n/a 2 614 (102 - 1 126) n/a 0.65
HbA1c (%) 42 9.1 (3.5) 8.0 - 10.2 14 9.0 (3.4) 7.0 - 11.0 0.89
Cholesterol (mmol/L) 12 4.5 (0.9) 4.0 - 5.1 7 3.9 (2.4) 1.7 - 6.2 0.573
Ferritin (µg/L) 23 976 (775) 642 - 1 310 14 2 381 (2 448) 1 157 - 3 605 0.045
CD4+ (HIV+) (cells/µL) 11 335 (221) 186 - 484 5 304 (193) 64 - 544 0.79
VL (HIV+) 10 LDL 3 LDL
D-dimer (mg/L)* 19 0.5 (0.3 - 1.1) n/a 9 0.6 (0.5 - 1.0) n/a 0.41
PT (s) 14 17.1 (8.8) 12.0 - 22.2 11 20.1 (23.7) 4.2 - 36.0 0.70
SaO2 = oxygen saturation; PaO2 = arterial partial pressure of oxygen; FiO2 = fraction of inspired oxygen; P/F ratio = partial pressure of arterial oxygen to fraction of inspired oxygen;  
PaCO2 = arterial partial pressure of carbon dioxide; WCC = white cell count; N/L ratio = neutrophil to lymphocyte ratio; MCV = mean cell volume; LDH; lactate dehydrogenase;  
ALT = alanine transaminase. HbA1c = glycated haemoglobin; VL = HIV viral load; PT = prothrombin time; LDL = lower than detectable limit; n/a = not applicable.
*Median (interquartile range).
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Discussion
In this early report of the first 116 COVID-19 patients admitted to 
a referral hospital in Cape Town, SA, serving a population with a 
high prevalence of HIV, we found that PLHIV did not appear to have 
significantly worse outcomes compared with their HIV-negative 
counterparts. Our population, despite being younger than many 
other reported populations, exhibited a similarly high prevalence 
of cardiovascular comorbidities, including hypertension, diabetes 
mellitus and obesity.
Perhaps unsurprisingly, given the high background prevalence 
of HIV in SA,[11] there was a higher prevalence of HIV in our study 
population compared with studies elsewhere.[12,13] However, the HIV 
prevalence in this early cohort (21%) appears to be almost double the 
estimated Western Cape provincial HIV prevalence of 12.6% in the 
age group 15 - 49 years.[11] The reasons for this proportionally higher 
burden of HIV in our COVID-19 admission population compared 
with the background prevalence are not immediately clear, and 
should be interpreted with caution. It is unclear whether unknown 
referral bias played a role, or whether patients with HIV represent 
an increased risk of hospitalisation compared with an HIV-negative 
population.
However, reassuringly, the HIV-positive patients did not exhibit 
increased mortality, as was predicted prior to the COVID-19 
pandemic reaching SA. The data from our study suggest that patients 
co-infected with HIV and SARS-CoV-2 have preserved CD4+ 
cell counts and suppressed HIV viral loads, and have concurrent 
cardiovascular comorbidities, including diabetes, hypertension and 
obesity. Interestingly, the CD4+ count and viral load did not differ 
between survivors and non-survivors with HIV, as may have been 
anticipated. However, the small sample size of HIV-positive patients 
limits drawing definitive conclusions on these matters, and larger 
cohort studies are urgently needed.
The proportion of patients in the study admitted to the ICU 
appears to be much higher than described in the UK[12] and in New 
York, USA.[14] The overall outcome in our study population, however, 
is similar to mortality rates described in the literature of ~24.5 - 
26%. [12,14] Encouragingly, the presence of HIV did not appear to 
influence outcome significantly. Significant risk factors for mortality 
in our population echo those in other populations around the world, 
namely low arterial partial pressure of oxygen, low P/F ratio, high 
CRP, high ferritin and high N/L ratio.
Study limitations
To our knowledge, this is the first cohort of >100 consecutive patients 
admitted with COVID-19 reported on the African continent, and from 
a population with a high burden of HIV and TB. However, our study 
has a number of limitations inherent in any study of this nature. Firstly, 
as this study was retrospective, data were not available for all variables, 
and were reliant on what was captured by the treating physician. 
For example, weight and body mass indices were not available for 
all patients, and information about obesity may have been under-
represented in this study. Secondly, as mentioned above, the sample 
size of HIV-positive patients was small, limiting definitive conclusions.
Conclusions
Our findings suggest that PLHIV with COVID-19 may have a high 
probability of admission to hospital, but had similar presentations, 
comorbidities and outcomes when compared with the HIV-negative 
study population. Large multicentre studies are needed to confirm 
these findings.
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